Skip to main content
Lilly calls it quits on baricitinib’s development for lupus
Primary tabs
•••
View
Get Stamp Tags
Published Locations
Breadcrumb
Home
Lilly calls it quits on baricitinib’s development for lupus
User login
Username
Password
Reset your password
Specialty
Lead
score
Rheumatology
1
1
Dermatology
0
0.9
Concept
Lead
score
Systemic Lupus Erythematosus
1
1
Dermatitis
0
0.67
Atopic Dermatitis
0
0.64
Food and Drug Administration (FDA)
0
0.64
Lupus
0
0.43
Arthritis
0
0.21
Clinical Research
0
0.99
Europe
0
0.21
Tumor
0
0.21
Rheumatoid Arthritis
0
0.14
COVID-19
0
0.1